University Of Montana System
Customers
3
3 federal agencies
Suppliers
1
1 federal subcontractor
Largest customer
—
No % disclosed
Named-customer revenue
—
No estimate available
Federal obligations
$16.4M
FY2024 · USAspending.gov
Federal contracts 3
Agencies that awarded contracts to this company, from USAspending.gov. Dollars are obligated amounts as reported, not estimates; $18.1M in the latest fiscal year shown per agency.
| Agency | Obligated | Fiscal year | Awards | Trend | Largest award |
|---|---|---|---|---|---|
| Department of Defense
Department of the Army |
$10.3M | FY 2024 | 6 | $12.2M → $10.3M | W911W618C0050 |
MSU - COST CONTRACT | |||||
| Department of Health and Human Services
National Institutes of Health |
$6.1M | FY 2024 | 5 | $12.8M → $6.1M | 75N93023C00047 |
DEVELOPMENT OF UM-1098: A NOVEL SYNTHETIC TH17 INDUCING ADJUVANT AND DELIVERY SYSTEM | |||||
| Department of Commerce
National Oceanic and Atmospheric Administration |
$1.7M | FY 2023 | 2 | 1305M223PNWWG0302 | |
UMRB PROJECT - MONTANA | |||||
Federal subcontractors 1
Companies this contractor subcontracted work to on federal prime contracts. From USAspending.gov subaward reports; amounts are as reported by the prime contractor, latest report per subaward, $500K+ a year.
| Company | Subawards | Fiscal year | Count | Trend | Largest subaward |
|---|---|---|---|---|---|
| Inimmune Corp | $713.5K | FY 2025 | 2 | 75N93023C00047 | |
THE VACCINE RESEARCH AND DEVELOPMENT TEAMS AT UNIVERSITY OF MONTANA (PI-EVANS), INIMMUNE (PI-BURKHART & MILLER), AND MOUNT SINAI (PI-KRAMMER) HAVE AN ESTABLISHED COLLABORATION FOR DEVELOPING LATE-STAGE ADJUVANTS AND FORMULATIONS WITH SUBUNIT ANTIGENS FROM INFLUENZA VIRUS (HA AND NA). THESE STUDIES HAVE DEMONSTRATED REMARKABLE PROTECTION AGAINST CHALLENGE WITH BOTH HOMOLOGOUS AND HETEROSUBTYPIC VIRUSES FOLLOWING IM OR IN VACCINATION WITH LEAD CANDIDATE VACCINES ADVANCING TO IND WITH CIVICS. WE PROPOSE TO EXPAND THIS WORK PERFORMED UNDER CIVICS AND ADJUVANT DEVELOPMENT CONTRACTS TO DEVELOP AND ADVANCE A DURABLE CROSS-PROTECTIVE ADJUVANTED H5N1 AND H5N2 SUBUNIT VACCINES. H5 AND N1 ANTIGENS FROM RECENT RELEVANT STRAINS AND CHALLENGE MODELS ARE ALREADY DEVELOPED AND AVAILABLE AT MOUNT SINAI. ADVANCED (CGMP PRODUCED) THERMOSTABLE ADJUVANTS AND FORMULATIONS ARE AVAILABLE FROM UM AND INIMMUNE. WE PROPOSE TO EVALUATE TRAC-478 (IM), SAS (IM), AND MUCOADHESIVE, TRAC-478, SAS, INI-2004 AND INI-4001 LIPOSOMES (INTRANASAL) FOR IMMUNOGENICITY WITH H5, N1/2 AND A COMBINATION H5+N1/2 ANTIGENS. COMPREHENSIVE EVALUATION OF VACCINE SAFETY AND IMMUNOGENICITY WILL BE CONDUCTED IN MICE, INCLUDING THE EVALUATION OF HUMORAL AND CELL MEDIATED IMMUNITY AS WELL AS VACCINE DURABILITY, DOSE SPARING, AND HETEROSUBTYPIC IMMUNITY ACROSS A RANGE OF H5N1 VARIANTS. LEAD CANDIDATE VACCINES WILL BE EVALUATED FOR PROTECTION USING AN ESTABLISHED H5N1 CHALLENGE MODEL IN MICE. THE PROJECT WILL SELECT A SINGLE LEAD VACCINE CANDIDATE FOR TRANSITION TO HUMAN CLINICAL EVALUATION. PROCESS DEVELOPMENT, SCALE-UP, CGMP MANUFACTURING AND GLP TOXICOLOGY TESTING OF THE LEAD VACCINE CANDIDATE IS INCLUDED IN OPTIONAL BUDGET PERIODS (YEARS 2 AND 3). THE FUNDING WOULD PROVIDE A PHASE I READY VACCINE WITH STRONG IND ENABLING PRECLINICAL POC AND SAFETY DATA. A NOVEL VACCINE INDUCING DURABLE HETEROSUBTYPIC IMMUNITY ACROSS A BROAD RANGE OF H5N1 VARIANTS IS CRITICAL FOR PANDEMIC PREPAREDNESS AS STOCKPILE OF THIS VACCINE WILL REMAIN EFFECTIVE ACROSS MANY YEARS OF ANTIGENIC DRIFT. | |||||
Alerts are coming
Get an email when University Of Montana System's disclosed suppliers or customers change. Join the list and we'll tell you when alerts launch. One email, no spam.